16:27:40 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-28 15-6 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-06-14 Ordinarie utdelning EMPLI 0.00 SEK
2023-06-13 Årsstämma 2023
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-02 Extra Bolagsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-11-14 Extra Bolagsstämma 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-04-07 Ordinarie utdelning EMPLI 0.00 SEK
2022-04-06 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Emplicure utvecklar produkter baserat på kombinationen av redan godkända aktiva substanser och materialvetenskap inom biokeramer, med skräddarsydda frisättningsprofiler som specialitet. Moderbolaget fokuserar på läkemedel, initialt mot kronisk smärta och med egenskaper som motverkar att de kan missbrukas. Via dotterbolag utvecklas konsumentprodukter, med oralt nikotin som första produktlinje. Sortimenten riktar sig till läkemedels- och konsumentnischer.
2023-02-17 14:08:11

Emplicure has decided to move forward with formulation development to increase the initial release profile of buprenorphine in Empli03. The decision was taken after final results from the exploratory pharmacokinetic study showed a steady extended release profile.

Empli03 is an oral buccal tablet containing the opioid buprenorphine for the treatment of moderate to severe pain. The exploratory clinical PK study is the first to investigate delivery of buprenorphine under the lip and final results demonstrate an extended release profile.

"The results show that our ceramic platform is a potent tool for controlled release of buprenorphine," said Håkan Engqvist, CEO of Emplicure. "This gives us the confidence to advance formulation development to increase the initial release profile. We believe Empli03 can play an important role in the treatment of moderate to severe pain, and potentially opioid use disorder."

After further positioning and formulation, Emplicure intends to find a partner for early-stage co-development of Empli03.

About the study

The objectives of the exploratory study were to examine the safety and tolerability of Empli03, and to analyze plasma concentrations of buprenorphine. Twelve healthy volunteers were dosed with a single oral buccal tablet placed under the upper lip for six hours and blood samples were collected throughout the study. All healthy volunteers completed the study, and no local irritation was observed. The tablet was easy to keep in place and was well-accepted.

Buprenorphine

Buprenorphine is approved to treat opioid use disorder and pain in major markets, including the US and EU. The safety profile of buprenorphine together with properties that limit abuse are important features that can contribute to safer medical treatment of pain..

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on February 17, 2023 at 14:08 CET.

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

The following documents can be retrieved from beQuoted
PM-Emplicure Empli03 2-ENG-2023-02-17.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com